Melane Sampson, Author at BioTuesdays

Developments

Precision doses first patient in study of in vivo gene editing program in DMD

Precision Biosciences (NASDAQ: DTIL) has announced the dosing of the first patient in August in the Phase 1/2 FUNCTION-DMD clinical trial evaluating its in vivo gene editing program, PBGENE-DMD, for the treatment of...

August 25, 2026

Developments

RMTG’s Cellgenic launches NK cell product line outside U.S.

Regenerative Medical Technology Group (RMTG) (OTCID: RMTG) has announced that its Cellgenic division has launched a natural killer (NK) cell product line for permitted markets outside the U.S., with an initial...

August 25, 2026

Developments

VERAXA and Secarna report positive results from AOC research collaboration

VERAXA Biotech (NASDAQ: VRXA) and closely held Secarna Pharmaceuticals have announced positive initial results from their research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs) for...

August 25, 2026

Developments

Oculis treats first patient in trial of Privosegtor in ON

Oculis Holding (NASDAQ: OCS; XICE: OCS) has announced that the first patient has been treated in the PIONEER-1 registrational trial evaluating Privosegtor for the treatment of optic neuritis (ON). According to Oculis...

August 25, 2026

Developments

Niagen expands Tru Niagen retail footprint

Niagen Bioscience (NASDAQ: NAGE) has announced that Tru Niagen, the company’s healthy-aging coenzyme nicotinamide adenine dinucleotide (NAD+)-boosting supplement, is now available at U.S. GNC and Sam’s Club retail...

August 20, 2026

Developments

Protagenic receives FDA pre-IND feedback for neuropeptide in GAD

Protagenic Therapeutics (OTCQB: PTIX) has announced that it has received written responses from the FDA to its Type B pre-Investigational New Drug (pre-IND) meeting request for PT00114, the company’s leading...

August 20, 2026

Executive Moves

Alejandro Carrillo joins Stemtech as president, Latin markets

Stemtech Corporation (OTCID: STEK) has announced the appointment of Alejandro Carrillo as president, Latin markets. Mr. Carrillo joined Stemtech as general manager of Stemtech Mexico in 2015, where he built the market...

August 20, 2026

Developments

Revive to build biodefence and pandemic preparedness portfolio

Revive Therapeutics (OTCQB: RVVTF; CSE: RVV; Frankfurt: 31R) has outlined its strategy to build a focused biodefence and pandemic preparedness medical-countermeasure portfolio led by bucillamine, a thiol-based drug with...

August 19, 2026

Developments

Sunshine receives approval for generic Enalapril in Canadian market

Sunshine BioPharma (NASDAQ: SBFM) has announced Canadian regulatory approval of its generic ACE inhibitor, Enalapril, in oral tablets of 2.5mg, 5mg, 10mg and 20mg for the treatment of hypertension, heart failure, and...

August 19, 2026

Developments

Revelation selects Avance Clinical as CRO for TITAN study

Revelation Biosciences (NASDAQ: REVB) has announced that it has selected Avance Clinical, a full-service contract research organization (CRO) with global operations, to serve as the CRO for its Phase 2/3 adaptive-design...

August 19, 2026

Author - Melane Sampson

Precision doses first patient in study of in vivo gene editing program in DMD

RMTG’s Cellgenic launches NK cell product line outside U.S.

VERAXA and Secarna report positive results from AOC research collaboration

Oculis treats first patient in trial of Privosegtor in ON

Niagen expands Tru Niagen retail footprint

Protagenic receives FDA pre-IND feedback for neuropeptide in GAD

Alejandro Carrillo joins Stemtech as president, Latin markets

Revive to build biodefence and pandemic preparedness portfolio

Sunshine receives approval for generic Enalapril in Canadian market

Revelation selects Avance Clinical as CRO for TITAN study

Subscribe